About the Company
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PROG News
Biora Therapeutics (BIOR) Price Target Decreased by 62.95% to 10.51
The average one-year price target for Biora Therapeutics (NasdaqGM:BIOR) has been revised to 10.51 / share. This is an ...
Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcript
Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcript March 26, 2024 Biora Therapeutics, Inc. isn't one of ...
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
The gross proceeds to Biora from this offering are expected to be approximately $6 million, before deducting the placement agent’s fees and other offering expenses. Biora intends to use the net ...
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
About Biora Therapeutics Biora Therapeutics is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free ...
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Mean Plasma Tofacitinib Concentration Following administration of a single oral dose of 5 mg and 10 mg BT-600 All ...
Biora Therapeutics, Inc. Common Stock (BIOR)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
Biora Therapeutics Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript
Welcome to the Biora Therapeutics Fourth Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow a formal ...
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent ...
Q4 2023 Biora Therapeutics Inc Earnings Call
Welcome to the Biora Therapeutics fourth quarter 2023 financial results call. (Operator Instructions) As a reminder, this conference is being recorded. I will now turn the call over to Chuck ...
Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcript
Biora Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Biora Therapeutics Fourth ...
Loading the latest forecasts...